Pentavalent antimonials: new perspectives for old drugs

Area of Science:

• Parasitology
• Medicinal Chemistry
• Pharmacology

Background:

• Pentavalent antimonials (meglumine antimoniate, sodium stibogluconate) are first-line leishmaniasis treatments.
• Limitations include severe side effects, parenteral administration, and emerging drug resistance.
• The exact mechanism of action and metabolism of antimonials remain under investigation.

Purpose of the Study:

• To review the current understanding of pentavalent antimony's chemistry and biochemistry.
• To summarize recent advancements in improving antimonial chemotherapy for leishmaniasis.
• To highlight novel formulation strategies for enhanced drug delivery.

Main Methods:

• Literature review of studies on pentavalent antimonials.
• Analysis of research on antimony's molecular structure, metabolism, and action mechanisms.
• Examination of new therapeutic approaches and drug delivery systems.

Main Results:

• Evidence suggests pentavalent antimony may act as a prodrug converted to active trivalent antimony, though direct action is also supported.
• Biomolecules like thiols and ribonucleosides may mediate antimonial drug actions.
• New strategies include simplified synthesis, liposome-based targeting, and cyclodextrin-based oral delivery.

Conclusions:

• Continued research into antimonial chemistry and biochemistry is crucial for understanding their therapeutic effects.
• Novel formulations offer promising avenues to overcome limitations of current antimonial treatments.
• Advancements in drug delivery aim to improve efficacy and patient compliance in leishmaniasis therapy.